The State of Biomarkers in Product Development

• Diagnostic Biomarkers
• Early Detection / Screening Biomarkers
• Predictive Biomarkers

• Prognostic Biomarkers
• Surrogate Biomarkers
• Toxicity Biomarkers

• Bioinformatics and Systems Biology
• Genomics
• Glycomics
• Histomics

• Imaging
• Metabolomics
• Proteomics

Report Content:

This report contains four major sections:

• Maturing Service Identifies Benefits of Early Strategy
• Outsourcing Strategies
• Sponsor Drivers and Roadblocks
• Trends in Biomarker Types and Technologies

As always, an appendix of Charts and Graphs is also included within this report with responses to all questions asked in this study.

What Readers Will Learn:

• Which CROs are viewed as having a credible biomarkers service offering 
• Current and future adoption of 6 different categories of biomarkers by drug developers 
• Barriers and drivers of biomarkers adoption 
• Sponsors' outsourcing intentions for products with biomarkers and for biomarker development 
• At what stages in development companies typically develop their biomarkers strategies

Companies Profiled:

• AAI
• Biomedical Systems
• CEDRA
• Covance
• DCRI-Duke
• i3 Pharma Services
• ICON
• Kendle (INC Research)
• Medpace
• PPD
• Quintiles
• US Oncology

Sample Graph:

Other Measurements In This Report:

• Preferred Service Providers for Biomarkers
• Most Credible Biomarker Providers
• Service Provider Differentiation Ideas
• Drivers for Biomarker Development

Similar Reports:

Purchasers of this report also purchased:

• The State of the Central Labs Market
• The Voice of the Site Coordinator
• Patient and Investigator Recruitment Success
• The State of Adaptive Clinical Trials